More than six decades after Calvin Stevens first synthesized ketamine at Parke-Davis in 1962 while diligently searching for a safer…
Read More
J&J Poster Puts Spravato Remission Data at Center of Treatment-Resistant Depression Growth Push
More than six decades after Calvin Stevens first synthesized ketamine at Parke-Davis in a quest for a safer anesthetic, the…
Read More
J&J Poster Puts Spravato Remission Data at Center of Treatment-Resistant Depression Growth Push
Johnson & Johnson is intensifying its efforts to expand the market footprint of Spravato (esketamine) for treatment-resistant depression (TRD), leveraging…
Read More
J&J Poster Puts Spravato Remission Data at Center of Treatment-Resistant Depression Growth Push
More than six decades after Calvin Stevens first synthesized ketamine at Parke-Davis while searching for a safer anesthetic, the molecule…
Read More
CDC Testing Pause Puts Clinical Labs at the Center of Public Health Response
The Centers for Disease Control and Prevention (CDC) has implemented a temporary suspension of its infectious disease testing services for…
Read More
CDC Testing Pause Puts Clinical Labs at the Center of Public Health Response
A temporary suspension of infectious disease testing services at the Centers for Disease Control and Prevention (CDC) has initiated a…
Read MoreYOU MAY HAVE MISSED
